CEO Ming Hsieh highlighted Phase 2 FID-007 data presented at ASCO, ongoing progress for FID-007 and FID-022, and efficiency gains from AI tools.
Q2 results and guidance
Fulgent Genetics posted Q2 2026 revenue of $85.4 million, up 4.38% from a year earlier.
GAAP net loss attributable to shareholders widened to $29.5 million, or $(1.05) per share, from $19 million, or $(0.62) per share.
Adjusted EBITDA loss increased to $17.1 million from $3 million.
Management cited processing delays tied to the final phase of a revenue cycle management and billing system transition as it cut full-year revenue guidance to $330 million-$340 million.
FLGT•
